Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABSK061 in Children With Achondroplasia
NCT07297875Phase 2Not yet recruiting
- Sponsor
- Abbisko Therapeutics
- Start
- Dec 2025
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lavengratinib in achondroplasia (ACH), sponsored by Abbisko Therapeutics. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
lavengratinib
03
Conditions
achondroplasia (ACH)
Beyond the preview
Go deeper on NCT07297875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07297875.